Thiogenesis Therapeutics (TSXV:TTI) Other Financing: C$0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:TTI Thiogenesis Therapeutics Corp TSXV:TTI
24 GF Score
Price C$0.54
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics Other Financing?

Thiogenesis Therapeutics TSXV:TTI 24 Other Financing is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSXV:TTI with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Thiogenesis Therapeutics's Other Financing for the three months ended in Mar. 2026 was C$0.00 Mil.

Thiogenesis Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.00 Mil.

Thiogenesis Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics Other Financing Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:TTI
24GF Score
Thiogenesis Therapeutics Corp TSXV:TTI
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of C$0.00 Mil mean?
Thiogenesis Therapeutics (TSXV:TTI) has a Other Financing of C$0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Thiogenesis Therapeutics and its competitors.
Is Thiogenesis Therapeutics' Other Financing too high?
Thiogenesis Therapeutics' current Other Financing is C$0.00 Mil. Overall, Thiogenesis Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' Other Financing compare to VRTX and REGN?
Thiogenesis Therapeutics' Other Financing of C$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current Other Financing is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TSXV:TTI) has a current Other Financing of C$0.00 Mil. The current Other Financing is C$0.00 Mil. Thiogenesis Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Thiogenesis Therapeutics (TSXV:TTI), the current Other Financing is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges TTIPF:USAQ8M:Germany
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
24GF Score

Get the complete analysis for TSXV:TTI

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.54
Price